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Objectives. This study was conducted to determine the effect of creased significantly fmm a mean 2 SEM of 552 f 80 to 390 + 
long-term digoxin therapy on autonomic function in patients with 3? ag/ml. In addition, the RR interval increased significantly from 
mild to moderate chmnic heart failure. 719 C 19 to 771 2 20 fils. Clgh frequency power increased from 
Buckground. Chronic heart failure is characterized by in- 84 + 24 to 212 z 72 ms*, and the root mean square of successive 
creased sympathetic activity and decreased parasympathetic ac- differences in RR interval increased from 20.3 f 1.8 to 27.0 + 
tivity. Intravenous digitalis has been found to reduce sympathetic 3.4 ms, indicating a substantial increase in parasympathetic 
activity immediately in these patients, hut whether short-term activity. Low frequency power, an index of baroreflex activity, was 
neurohormonal effects are sustained during long-term oral ther- also significantly increased (239 2 80 to 483 -C 144 ms*) by 
apy has not been assessed. digoxin therapy. 
iMethods. We determined sympathetic activity in 26 patients 
with heart failure by measuring plasma norepinephrine levels and 
parasympathetic activity from variables of heart period variability 
derived fmm 24-h ambulatory electrocardiographic Halter record- 
ings obtained before and after 4 to 8 weeks of digoxin therapy. 
Co&u.vions. These results indicate I) that long-term therapy 
with digoxin acts to ameliorate the autonomic dysfunction of 
patients with brat-t failure, and 2) that the short-term neurohor- 
monal effects of digo.xin are sustained during prolonged treatment 
with the drug. 
Resuh. After digoxht therapy, plasma norepinephrine de- (J Am Coil Cardiol1995;25:289-94) 
Digoxin is widely used in the treatment of chronic heart failure. 
The benefit of digoxin in this condition has been supported by 
the results of several double-blind, placebo-controlled studies 
that have demonstrated salutary clinical effects of this drug in 
patients with chronic heart failure and normal sinns rhythm. 
These effects include improvement in exercise tolerance and 
functional capacity and a decreased need for hospital admis- 
sion for worsening heart failure (l-4). 
in similar (if not greater) hemodynamic improvement yet has 
failed to produce favorable long-term outcomes in patients 
with heart failure (6-9). Therefore, the long-term benefits of 
digoxin in this condition may not be due solciv to the drug’s 
hemodynamic actions. 
The clinical benefits observed with digoxin in patients with 
heart failure have traditionally been attributed to the bemo- 
dynamic improvements produced by this agent: that is, in- 
iL..+:-- creases in cardiac output and left ventricular ejc&ir UUIUII 
together with decreases in cardiac filling pressures and vol- 
umes (2,3,5). However, it is not clear that the clinical benefits 
of digoxin are related to its hemodynamic actions, because 
therapy with other positive inotropic agents (such as beta- 
adrenergic agonists and phosphodiesterase inhibitors) results 
Considerable attention has recently been focused on addi- 
tional pharmacologic actions of digoxin that are independent 
of its positive inotropic properties; for example, in contrast to 
other inotropic agents, digoxin reduces sympathetic activity in 
patients with heart failure. Single doses of digitalis inhibit the 
outflow of sympathetic impulses from the central nervous 
From the Division of Circulatory Physiology and Center for Heart Failure 
Research and Division of Cardiology, Columbia University, College of Physi- 
cians an? Surgeons, New York, New York. Dr. Krum was an Overseas Research 
Fellow of the National Heart Foundation of Australia, Canberra, Australian 
Capital Territory, for .e tr,rure of this study. 
Manuscript rc. /ed July 1,1994; revised manuscrip! received September 7, 
1994, accepted September 22,1994. 
’ . >y&,i~as dei*:Ein,ya +om m:c:o::eur~qqmic recordings 
(i(l) and decreased levels of plasma norepinephrine (11). 
However, the long-term effects of digoxin on sympathetic 
activation in patients with heart failure have yet to be evalu- 
ated. As progression of disease and mortality in chronic heart 
failure may be directly related to the degree of sympathetic 
activation associated with the condition (12), long-term ther- 
apy with drugs that inhibit sympathetic activity may favorably 
influence clinical outcome. 
m: Dr. Rochege L. Goldsmith, Division of Circu- 
latory Physiology, Columbia University College of Physicians and Surgeons, 630 
West 168 Street, New York, New York 10032. 
In addition to sympathetic nervous system activation in 
chronic heart failure, there appears to be marked suppression 
of the activity of the parasympathetic nervous system (13). 
Both the increase in heart rate that occurs after the adminis- 
tration of atropine and the baroreceptor-mediated slowing of 
heart rate that occurs after the administration of phenyleph- 
rine are markedly less in patients with heart failure, than in 
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normai control subjects (13). In normal subjects And in aili- 
mals, digoxin enhances baroreceptor-nlediated increases in 
vagal tone (14), sensitizes muscarinic recepturs on rhe vagus 
(15) and enhances efferent acetylcholine-mediated vagal neu- 
ral transmission (16). However, the effects of long-term digoxin 
therapy on parasympathetic activity have not been evaluated in 
patients with heart failure. 
The aim of the present study, therefore, was to evaluate the 
effect of long-term digoxin therapy on the activity of both the 
sympathetic and the parasympathetic nervous system in pa- 
tients with chronic heart failure to assess whether the short- 
term autonomic effects of the drug are sustained with long- 
term therapy. 
Methods 
Study patients. We evaluated 26 patients (13 men) re- 
ferred to the Heart Failure Center at Columbia-Presbyterian 
Medical Center for evaluation of chronic heart failure. Their 
mean age + SEM was 55.5 -C 2.1 years. The cause of heart 
failure was idiopathic dilated cardiomyopathy in 16 patients, 
ischemic heart disease in 8, peripartum cardiomyopathy in 1 
patient and hypertensive heart disease in i paiient. Six patients 
were classified in New York Heart Association functional class 
I (agmptomaticj at s:udy cntiry. Of these six patieiits, five had 
previoudy had hear! failure but symptoms had disappeared 
with therapy. Twelve patients had functional class II symptoms 
and eight had class III symptoms. Mean left ventricular 
ejection fraction, as determined by radionuclide ventriculogra- 
phy, was 21.5 +- 1.6%. All patients were in clinically stable 
condition, had normal sinus rhythm and had no overt signs of 
fluid retention. 
Twenty-one patients were receiving diuretic agents and 
angiotciisiii-c.cr~verting enzyme inhibitors, foor were receiving 
&xrctic agents alone and one patient was not receiving back- 
ground therapy. Patients not receiving ci+&ensin-converting 
enzyme inhibitors were unable to tolerate these agents (usually 
because of cough). Doses of diuretic therapy remained con- 
stant for 21 week before study entry and doses of angiotensin- 
converting enzyme inhibitors were stable for ~2 weeks before 
study entry. No patient had previously received digoxin ther- 
apy, and none was currently receiving beta-blockers, calcium 
channel blockers, antiarrhythmic agents, bronchodilators or 
s;ltihypertensive medications (except diuretic drugs). 
No patient had a recent (<3 months) history of myocardial 
infarction, episode of unstable angina or stroke and none had 
heart failure due to hypertrophic or amyloid cardiomyopathy. 
All patients had a serum creatin’ne level ~3.0 mg/dl and none 
had a concomitant condition that might produce autonomic 
dysfunction (e.g., diabetes mellitus). 
Study design. The protocol was approved by the Institu- 
tional Review Board of the Columbia University College of 
Physicians & Surgeons and patients provided written, informed 
consent. At baseline, blood was collected for measurement of 
plasma norepinephrine, and 24-h Holter ambulatory electro- 
cardiographic (ECG) recordings were performed to allow 
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analysis of heart perind variability. After completion of the 
Hoiter recording, digoxin therapy was initiated at a dose 
determined by the patient’s age and renal function. These 
doses were 0.25 mg/day (in patients ~70 years old with a serum 
creatine level cl.5 mgidl), 0.125 mgiday (in patients <70years 
old with a serum creatinine level >1.5 mg/dl or patients ~70 
years old with a serum creatinine level cl.5 mg/dl) and 
0.125 mg every other day (in patients >70 years old with a 
serum creatinine level b1.5 mg/dl). 
Digoxin therapy was continued for 4 to 8 weeks; concomi- 
tant therapy was maintained in unchanged doses. 
At the end of the study period, as during the first visit, blood 
was collected for meavJrement of plasma ievels of norepineph- 
rine and serum digoxin, and a second 24-h Holter recording 
was obtained to assess measures of heart period variability, 
Measurement of plasma norepinephrine. After placement 
of an intravenous cannula, patients rested supine for 30 min in 
a quiet, darkened room while blood was collected into pre- 
chilled lithium-heparin tubes for determination of plasma 
norepinephrine levels. All tubes were placed immediately on 
ice, centrifuged at 2.500 rpm at 4°C for 10 min, then immedi- 
ately stored frozen at -70°C for later analysis. Samples were 
analyzed within 48 h of collection. Plasma nurepinephrine was 
measured in a reference laboratory by high performance liquid 
chromatography with electrochemical detection (17). 
Hoiter ECG recordings. Dual-lead ECG recordings (Icads 
CMp and CM,) were made on Marquette 8500 Holter record- 
ers. These recorders contain a digital clock to provide a time 
signal that is continuously recorded on the tape. The Holter 
tapes Weic digitized on a Marquette series 8000 scanner. The 
signa! XX campled at 128 Hz. Sampling was triggered by th.2 
timing track on the tape to correct for flutter and wow of 
the recording or playback tape transport. QRS complex rec- 
ognition and arrhythmia de tecti:;.l were done automatically by 
template matching. This system generates a beat by beat 
annotation of the ECG with a consistent and accurate time 
stamp for each QRS complex and classifies each complex as 
normal sinus, atria1 or ventricular premature complex or noise. 
The decisions made: automatically by the computer were 
reviewed and correctfd by an experienced technician and then 
by a cartiioiogisr. Tit + digitized ECG, QRS trigger list and 
report data were then transferred over a high speed direct 
memory access link LO a $1~ _Microsystems 4/75 computer 
where additional editing on the sorted intervals and further 
analysis, including time and frequency domain analysis of heart 
period variability, we;e performed. Each completed analysis, 
comprising 50 megabftes of dig&ed ECG and a QRS trigger 
list, was stored on laser disk. The 24-h heart period power 
spectrum was computed by using a fast Fourier transform on 
data for the entire 24-h period (18,19). Low frequency power 
(0.04 to 0.15 Hz) reflects modulation of both sympathetic and 
parasympathetic tone by baroreflex activity, whereas high 
frequency power (0.15 to 0.40 Hz) reflects modulation solely of 
parasympathetic tone by breathing. Both low and high fre- 
quency power were computed by integrating over their fre- 
quency intervals. In addition, the ratio of low to high frequency 
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Table 1. Heart Period Variability Before and After I to 8 Weeks of Digoxin Therapy 
BCfO‘orC After P 
Heart Period Variabili? Measures Digoxin Digodn Value” 
I____ 
Average normal RR inlcrval for 24 h (ms) 719 c 19 771 t 21) 11.111~14 
24-h standard deviation of normal RR 90 LT 9 115 r 10 0.0137 
intervals (ms) 
Root mean successive difference square 20.3 2 1.8 27.0 z 3.4 0.0517 
Percent of adjacent normal RR inttzvals >5O ms 4.9 t 1.0 8.0 _f 1.8 0.0041 
Total (~0.40 Hz) (ms”) power 9,896 rt 2,193 16,698 i 3,371 
Natural logarithm total power 8.7 t 0.2 9.4 t 0.2 0.0006 
Low frequency (0.04-0.15 Hz) (ms?) power 239 z 80 483 _C 144 
Natural logarithm low frequency power 4.5 2 0.3 5.4 t- 0.3 0.0004 
High frequency p,>wer (0.15-0.40 Hz) (m?) 84.2 t 24.1 212 + 12 
Natural logarithm high frequency power 3.7 i- 0.3 4.j t 0.3 0.0057 
Ratio of lr w to high frequency power 2.4 ir 0.2 3.1 t- 0.5 0.1021 
-~ 
*p valu :s compare values before and after digoxin, as analyzed by paired I test. Because frequency domain measures 
of heart period variability were positively skewed, these data were natural logarithm transformed before parametric 
analysis. !I,!, presented are mean value rt SEM. 
power, which has been proposed as a marker of sympathovagal 
balance (20), was calculated. Time domain measures of para- 
sympathetic activity--specifica!!y the root mean square of 
successive differences and the percent of heart period differ- 
ences X0 ms-were also measured. These time domain 
measures are highly correlated with one another as well as with 
high frequency power (21) and cas’ therefore be used inter- 
changeably as measures of parasympathetic activity. In addi- 
tion, the 24-h standard deviation of normal RR intervals, a 
marker of overall heart period variability, was measured. 
Although not a pure measure of parasympathetic activity, it 
has been found (22) to be predictive of mortality in patients 
after myocardia! infarction. 
Statistical analysis. The effect of digoxin on sympathetic 
and parasympathetic activity was assessed by comparing post- 
treatment with pretreatment values for plasma norepinephrine 
and Holter-derived measures of heart period variability. 
Previous studies have demonstrated that the distributions 
of the frequency domain measures of heart period variability 
are positively skewed (23). Because of this skewness, the 
frequency domain data in the present study were transformed 
to their natural logarithms to achieve a normal distribution: 
this transformation permitted parametric statistical analysis. 
Differences in values at baseline and during digoxin therapy 
were tested for statistical significance by using the paired t test. 
In addition, possible associations between changes in plasma 
norepinephrine and Holter measures after digoxin therapy 
were evaluated for statistical significance by linear regression 
analysis. All results are expressed as mean value +- SEM. 
Results 
Digoxin was administered to all 26 patients for a total of 4 
to 8 weeks (mean 4.6); the mean serum iigoxin levels was 
1.1 2 0.1 rig/ml at the end of the study period. 
Plasma norepinephrine levels decrea,J si,Aficantly after 
digoxin therapy by 42% from 552 -C 80 to 34r. ? 37 &ml (p < 
0.05). The decrease in plasma norepinephrine wa; greatest in 
those patients who had the highest plasma norepinephrine 
levels before treatment (r = 0.70 for the correlation of 
pretreatment plasma norepinephrine vs. change in plasma 
norepinephrice, p < 0.001). 
There was a modest, statistically significant increase in 24-h 
average Rk interval during digoxin therapy from 719 t- 19 ms 
to 771 t 20 ms, corresponding to a slowing of heart rate from 
83 to 79 beatslmin with the drug (Table 1). The high frequency 
(0.15 to 0.40 Hz) component of the 24-h heart period variabil- 
ity power spectrum increased significantly during therapy with 
digoxin (p < O.Ol), indicating a substantial increase in cardiac 
parasympathetic activity (Table 1, Fig. 1). In addition, the low 
frequency power spectrum also increased significantly during 
digoxiu therapy (p < O.OOl), despite the decrease in plasma 
norepinephrine (Table 1, Fig. 1). Furthermore, the time do- 
main measures of heart period variability that reflect cardiac 
parasympathetic activity (i.e., root mean square of successive 
RR interval differences and percent of heart period differences 
>50 ms) also increased during digoxin therapy in these pa- 
tients (by 33% and 63% respectively (Table 1, Fig. 2). Despite 
the substantial increase in high frequency power during digoxin 
therapy, there was no significanr changer: in the ratio of low to 
high frequency power (p = 11.10), reflecting concomitant 
increases in low frequency power. 
Serum digoxin level was the only variable measured that 
was correlated with the parampathetic response to digoxin 
therapy. Serum digoxin levels correlated directly with changes 
in parasympathetic activity as determined from measures of 
heart period variability; that is, patients with the highest serum 
digoxin levels had the largest increases in high frequency 
power (r = 0.59, p < 0.05). In contrast, serum digoxin levels 
were not correlated with changes in plasma norepinephrine 
level during digoxin therapy. In addition, there was no corre- 
lation between age, functional class or left ventricular ejection 
fraction assessed at baseline and autonomic responses to 
therapy. Changes in sympathetic activity as determined by 
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changes in plasma norepinephrine levels during therapy with 
digoxin were not correlated with changes in parasympathetic 
activity as determined from heart period variability measures. 
Discussion 
The present study demonstrates that long-term therapy 
with digoxin results in a significant increase in parasympathetic 
activity and a decrease in sympathetic activity in patients with 
chronic heart failure. 
Several well validated measures of beat to beat variations in 
normal RR intervals are available to assess parasympathetic 
nervous system activity in humans (24-26). With these tech- 
niques, parasympathetic withdrawal has been found (13,27) to 
be a prominent component of the autonomic dysfunction that 
accompanies chronic heart failure, thereby confirming similar 
conclusions obtained by established techniques (13). However, 
the role of digoxin in modulating parasympathetic activity has 
not been extensively studied in patients with heart failure. The 
present findings demonstrate significant and persistent in- 
creases in parasympathetic activity during long-term digoxin 
therapy as indicated b!f the substantial increases in high 
frequency power, root medi;. square of successive RR interval 
differences and percent of heart period differences >50 ms. 
These results are consistent with observations (28) of substan- 
in Low Frequency In High Frequency 
Power (ms2) Power (ms*) 
Baseline Digoxin Baseline Digoxin 
l =p < o.a5 
Figure 1. Effect of long-term digoxin therapy on time 
domain measures of 24-h heart period variability in pa- 
tients with chronic heart failure. With digoxin therapy, 
vaiucs for standard deviation of sccccssive RR intervals 
(SDNN), root mean square of successive RR interval 
differences (r-MSSD) and percent adjacent RR intervals 
150 ms (pNNS0) increased (p 5 0.0s) with respect to 
baseline values. 
tial increases in parasympathetic activity with long-term ad- 
ministl-ation of this drug to normal subjects. 
Sympathetic activity, as determined from measurement of 
plasma norepinephrine Icvel;, was significantly reduced by 
long-term digoxin therapy in these patients. Previous studies of 
short-term administration of digoxin in patients with chronic 
heart failure have demonstrated both acute peripheral vasodi- 
lation (29) and reductions in sympathetic nerve traffic (10) and 
plasma norepinephrine levels (11). The present data confirm 
that these e&ts are sustained during long-term therapy with 
digoxin, and are consistent with a recent report (30). 
Measurement of heart period variability in our study dem- 
onstrated an increase in low frequency power with long-term 
digoxin therapy. Low frequency RR interval rhythms are 
jointly mediated by fluctuations of vagal and sympathetic nerve 
activity (24,31) and are attributed to the modulation of heart 
rate by baroreflex mechanisms (32). Because plasma norepi- 
nephrine levels decreased with digoxin therapy in the present 
study, the increase in absolute low frequency power noted in 
our study is unlikely to be accounted for by increases in 
sympathetic activity. Moreover, hecatse low frequency power 
has been demonstrated (32) to be correlated with the degree 
of baroreflex-mediated vagal stimulation, our finding of in- 
creased low frequency power may reflect baroreflex sensitiza- 
LF/HF Ratio 
I 
Baseline Digoxin 
* 5 p c 0.05 
Figure 2. Effect of long-term digoxin therapy on fre- 
quency domain measures of 24-h heart period variability 
in patients with chronic heart failure. With digoxin ther- 
apy, natural logarithm low and high frequency power 
increased significantly (p 5 0.05) with respect to baseline 
values. The low frequency/high frequency (LFMF) ratio 
was unaltered by digoxin therapy. 
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tion, thcrebjr supporting previous observations that digosin 
sensitizes cardiac and aortic baroreccptors (15.33). 
The changes w observed in autonomic function with 
long-term digoxin therapy are particularly noteworthy given 
the characteristics of our study group. Our patients had 
relatively mild hca,rt failure as assessed by NW York Hcari 
Association functiona: class. &cause severity of disease is 
closely correlated with degree of sympathetic activation, 
plasma norepinephrine levels would sot be expected to be 
greatly elevated at base!ine or to be significantly reduced by 
therapy in such patients. Nevertheless, long-term therapy with 
digoxin in this group did result in significant reductions in 
sympathetic activity as measured by plasma norepinephrine 
levels. Patients with the highest baseline norepinephrine levels 
had the greatest decreases in plasma norepinephrine. This 
finding could be accounted for, in part, by regression toward 
the mean; however it is also consistent with the suggestion that 
the degree of sympathoinhibition with digoxin is related to the 
degree of neurohormonal activation (34). Furthermore, most 
patients were receiving angiotensin-converting-enzyme inhibi- 
tors, drugs that themscives decrease sympathetic (3.5) and 
increase parasympathetic (36) activity in patients with heart 
failure. Despite the presence of these agents as background 
therapy, long-term digoxin therapy further decreased sympa- 
thetic and increased parasympathetic nervous system activity. 
This finding may be of some importance as angiotensin- 
converting enzyme inhibitors are now standard therapy for 
patients with chronic heart failure. 
catieW Viih ksart failure (12). Thoss uitk tke greatest degree 
of sympathetic activation, as determined hy plasma norepi- 
nephrine levels, have been found to have the highest mortality 
rate. This relation may not necessarily be causal: howcvcr. 
e*cess catccholamine secretion does have profound direct toxic 
elects on the myocardium and may potentiate arrhythmias 
(42). A National institutes of Health cooperative study and 
Veterans Affairs Administration study (Digoxin Intervention 
Group [DIG] Study) is currently investigating these theoreti- 
cally beneficial effects of digoxin on mortality in patients with 
heart failure. 
Conchsions. The present study demonstrates that digoxin 
causes significant reductions in sympathetic activity together 
with large increases in parasympathetic modulation of RR 
intervals in patients with mild to moderate congestive heart 
failure. The effects of digoxin therapy on autonomic function 
persisted for the 4 to 8 weeks of our study; thus, the beneficial 
neurohormonal effects of digoxin previously described during 
short-term therapy tire sustained during long-term treatment 
with the drug, 
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